Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Attenuated expression of HRH4 in colorectal carcinomas: a potential influence on tumor growth and progression

Authors: Zhengyu Fang, Wantong Yao, Yi Xiong, Jiana Li, Li Liu, Lei Shi, Wei Zhang, Chao Zhang, Liping Nie, Jun Wan

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Earlier studies have reported the production of histamine in colorectal cancers (CRCs). The effect of histamine is largely determined locally by the histamine receptor expression pattern. Recent evidence suggests that the expression level of histamine receptor H4 (HRH4) is abnormal in colorectal cancer tissues. However, the role of HRH4 in CRC progression and its clinical relevance is not well understood. The aim of this study is to evaluate the clinical and molecular phenotypes of colorectal tumors with abnormal HRH4 expression.

Methods

Immunoblotting, real-time PCR, immunofluorescence and immunohistochemistry assays were adopted to examine HRH4 expression in case-matched CRC samples (n = 107) and adjacent normal tissues (ANTs). To assess the functions of HRH4 in CRC cells, we established stable HRH4-transfected colorectal cells and examined cell proliferation, colony formation, cell cycle and apoptosis in these cells.

Results

The protein levels of HRH4 were reduced in most of the human CRC samples regardless of grade or Dukes classification. mRNA levels of HRH4 were also reduced in both early-stage and advanced CRC samples. In vitro studies showed that HRH4 over-expression caused growth arrest and induced expression of cell cycle proteins in CRC cells upon exposure to histamine through a cAMP -dependent pathway. Furthermore, HRH4 stimulation promoted the 5-Fu-induced cell apoptosis in HRH4-positive colorectal cells.

Conclusion

The results from the current study supported previous findings of HRH4 abnormalities in CRCs. Expression levels of HRH4 could influence the histamine-mediated growth regulation in CRC cells. These findings suggested a potential role of abnormal HRH4 expression in the progression of CRCs and provided some new clues for the application of HRH4-specific agonist or antagonist in the molecular therapy of CRCs.
Appendix
Available only for authorised users
Literature
1.
Yang X, Wan DS: [Roles of insulin-like growth factor system in colorectal carcinoma and its applications]. Ai Zheng. 2005, 24: 1161-1164.PubMed
2.
Collins TS, Hurwitz HI: Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol. 2005, 32: 61-68.CrossRefPubMed
3.
Guba M, Seeliger H, Kleespies A, Jauch KW, Bruns C: Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis. 2004, 19: 510-517.CrossRefPubMed
4.
Venook AP: Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer. 2005, 103: 2435-2446.CrossRefPubMed
5.
Kurtin SE: Targeting the epidermal growth factor receptor in colorectal carcinoma. Cancer Nurs. 2007, 30: S1-9.CrossRefPubMed
6.
Yarom N, Jonker DJ: The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med. 11: 95-105.
7.
Medina MA, Quesada AR, Nunez de Castro I, Sanchez-Jimenez F: Histamine, polyamines, and cancer. Biochem Pharmacol. 1999, 57: 1341-1344.CrossRefPubMed
8.
Suonio E, Tuomisto L, Alhava E: Effects of histamine, H1, H2 and Hic receptor antagonists and alpha-fluoromethylhistidine on the growth of human colorectal cancer in the subrenal capsule assay. Agents Actions. 1994, 41 (Spec No): C118-120.CrossRefPubMed
9.
Masini E, Fabbroni V, Giannini L, Vannacci A, Messerini L, Perna F, Cortesini C, Cianchi F: Histamine and histidine decarboxylase up-regulation in colorectal cancer: correlation with tumor stage. Inflamm Res. 2005, 54 (Suppl 1): S80-81.CrossRefPubMed
10.
Hellstrand K, Brune M, Mellqvist UH, Naredi P: Histamine, cimetidine and colorectal cancer. Nat Med. 1996, 2: 364-365.CrossRefPubMed
11.
Molnar EL, Cricco G, Martin G, Darvas Z, Hegyesi H, Fitzsimons C, Bergoc R, Falus A, Rivera E: Histamine as a potential autocrine regulator of melanoma. Inflamm Res. 2001, 50 (Suppl 2): S102-103.CrossRefPubMed
12.
Malaviya R, Uckun FM: Histamine as an autocrine regulator of leukemic cell proliferation. Leuk Lymphoma. 2000, 36: 367-373.CrossRefPubMed
13.
Garcia-Caballero M, Neugebauer E, Campos R, Nunez de Castro I, Vara-Thorbeck C: Increased histidine decarboxylase (HDC) activity in human colorectal cancer: results of a study on ten patients. Agents Actions. 1988, 23: 357-360.CrossRefPubMed
14.
Reynolds JL, Akhter J, Adams WJ, Morris DL: Histamine content in colorectal cancer. Are there sufficient levels of histamine to affect lymphocyte function?. Eur J Surg Oncol. 1997, 23: 224-227.CrossRefPubMed
15.
Backhaus B, Weidenhiller M, Bijlsma P, Hahn EG, Raithel M: Evaluation of spontaneous histamine release from colorectal mucosa in patients with colorectal adenoma, patients with gastrointestinally mediated allergy and in a healthy control group. Inflamm Res. 2004, 53 (Suppl 1): S87-88.CrossRefPubMed
16.
Nielsen HJ, Hammer JH, Moesgaard F, Kehlet H: Possible role of histamine-2 receptor antagonists for adjuvant treatment in colorectal cancer. Clinical review. Eur J Surg. 1991, 157: 437-441.PubMed
17.
Petit-Bertron AF, Machavoine F, Defresne MP, Gillard M, Chatelain P, Mistry P, Schneider E, Dy M: H4 histamine receptors mediate cell cycle arrest in growth factor-induced murine and human hematopoietic progenitor cells. PLoS One. 2009, 4: e6504-CrossRefPubMedPubMedCentral
18.
Medina V, Croci M, Crescenti E, Mohamad N, Sanchez-Jimenez F, Massari N, Nunez M, Cricco G, Martin G, Bergoc R, Rivera E: The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther. 2008, 7: 28-35.CrossRefPubMed
19.
Cricco GP, Mohamad NA, Sambuco LA, Genre F, Croci M, Gutierrez AS, Medina VA, Bergoc RM, Rivera ES, Martin GA: Histamine regulates pancreatic carcinoma cell growth through H3 and H4 receptors. Inflamm Res. 2008, 57 (Suppl 1): S23-24.CrossRefPubMed
20.
Sander LE, Lorentz A, Sellge G, Coeffier M, Neipp M, Veres T, Frieling T, Meier PN, Manns MP, Bischoff SC: Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut. 2006, 55: 498-504.CrossRefPubMedPubMedCentral
21.
Boer K, Helinger E, Helinger A, Pocza P, Pos Z, Demeter P, Baranyai Z, Dede K, Darvas Z, Falus A: Decreased expression of histamine H1 and H4 receptors suggests disturbance of local regulation in human colorectal tumours by histamine. Eur J Cell Biol. 2008, 87: 227-236.CrossRefPubMed
22.
Cianchi F, Cortesini C, Schiavone N, Perna F, Magnelli L, Fanti E, Bani D, Messerini L, Fabbroni V, Perigli G, et al: The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res. 2005, 11: 6807-6815.CrossRefPubMed
23.
Demicheli R, Foroni R, Ingrosso A, Pratesi G, Soranzo C, Tortoreto M: An exponential-Gompertzian description of LoVo cell tumor growth from in vivo and in vitro data. Cancer Res. 1989, 49: 6543-6546.PubMed
24.
Quinn LA, Moore GE, Morgan RT, Woods LK: Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. Cancer Res. 1979, 39: 4914-4924.PubMed
25.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408.CrossRefPubMed
26.
Chen Y, Liu H, Liu Z, Liang S, Chen J, Long F, Peng Y, Yan L, Gong J: Blockade of inducible costimulator pathway to prevent acute rejection in rat liver transplantation. Am J Surg. 2009, 198: 244-249.CrossRefPubMed
27.
Buckland KF, Williams TJ, Conroy DM: Histamine induces cytoskeletal changes in human eosinophils via the H(4) receptor. Br J Pharmacol. 2003, 140: 1117-1127.CrossRefPubMedPubMedCentral
28.
Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP: Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther. 2003, 305: 1212-1221.CrossRefPubMed
29.
Sugata Y, Okano M, Fujiwara T, Matsumoto R, Hattori H, Yamamoto M, Nishibori M, Nishizaki K: Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses. Immunology. 2007, 121: 266-275.CrossRefPubMedPubMedCentral
30.
Matsuda N, Teramae H, Futatsugi M, Takano K, Yamamoto S, Tomita K, Suzuki T, Yokoo H, Koike K, Hattori Y: Up-regulation of histamine H4 receptors contributes to splenic apoptosis in septic mice: counteraction of the antiapoptotic action of nuclear factor-kappaB. J Pharmacol Exp Ther. 332: 730-737.
31.
Werner JM, Eger K, Jurgen Steinfelder H: Comparison of the rapid pro-apoptotic effect of trans-beta-nitrostyrenes with delayed apoptosis induced by the standard agent 5-fluorouracil in colon cancer cells. Apoptosis. 2007, 12: 235-246.CrossRefPubMed
32.
Backus HH, Pinedo HM, Wouters D, Kuiper CM, Jansen G, van Groeningen CJ, Peters GJ: Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. Oncol Res. 2000, 12: 231-239.PubMed
33.
Cheng JD, Werness BA, Babb JS, Meropol NJ: Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma. Clin Cancer Res. 1999, 5: 1057-1062.PubMed
34.
Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13: 1501-1512.CrossRefPubMed
35.
Cam WR, Masaki T, Shiratori TY, Kato N, Okamoto M, Yamaji Y, Igarashi K, Sano T, Omata M: Activation of cyclin E-dependent kinase activity in colorectal cancer. Dig Dis Sci. 2001, 46: 2187-2198.CrossRefPubMed
36.
McKay JA, Douglas JJ, Ross VG, Curran S, Ahmed FY, Loane JF, Murray GI, McLeod HL: Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin Cancer Res. 2000, 6: 1113-1118.PubMed
37.
Rao S, Gray-Bablin J, Herliczek TW, Keyomarsi K: The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway. Exp Cell Res. 1999, 252: 211-223.CrossRefPubMed
Metadata
Title
Attenuated expression of HRH4 in colorectal carcinomas: a potential influence on tumor growth and progression
Authors
Zhengyu Fang
Wantong Yao
Yi Xiong
Jiana Li
Li Liu
Lei Shi
Wei Zhang
Chao Zhang
Liping Nie
Jun Wan
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-195

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas

Research article

Integrated genomics of ovarian xenograft tumor progression and chemotherapy response

Research article

Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection

Research article

The effect of breast cancer awareness month on internet search activity - a comparison with awareness campaigns for lung and prostate cancer

Research article

Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression

Research article

The association of APE1 −656T > G and 1349 T > G polymorphisms and cancer risk: a meta-analysis based on 37 case-control studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits